Geron Corporation GERN
Set alert
As of Nov 2, 11:11 AM ET
- YTD
- -31.75%
- 1 year
- -28.50%
- Open
- 0.90
- Prev close
- 0.8944
- Mkt cap
- 578.93M
- Vol
- 3.26M
- Avg vol
- 11.46M
- EPS
- -0.11
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.8847
- High
- 0.9197
- Forward P/E
- 39.25
- Beta
- 0.60
- Short ratio
- 7.70
- Inst. own
- 76.50%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 1.47
- 200-d avg
- 1.44
- 1y target
- 4.25
5D chart
Signals (74)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 10:50 AM | 21 minutes ago |
| SMA: Bearish | Nov 2, 10:45 AM | 26 minutes ago |
| SMA: Bullish | Nov 2, 9:55 AM | 1 hour ago |
| SMA: Bearish | Nov 2, 9:40 AM | 1 hour ago |
| SMA: Bullish | Oct 30, 3:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:10 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:30 PM | 2 days ago |
| RSI: Oversold | Oct 30, 2:00 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 1:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:45 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:30 PM | 2 days ago |
| RSI: Oversold | Oct 30, 12:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:25 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:15 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:35 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:45 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:40 AM | 3 days ago |
| SMA: Bearish | Oct 29, 4:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:15 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:00 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:25 PM | 3 days ago |
| RSI: Oversold | Oct 29, 12:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:05 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 11:00 AM | 4 days ago |
| MACD: Buy Signal | Oct 29, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:10 PM | 4 days ago |
| RSI: Overbought | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:10 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 28, 11:55 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:50 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:40 AM | 5 days ago |
| RSI: Oversold | Oct 28, 11:05 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:55 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:35 AM | 5 days ago |
| RSI: Oversold | Oct 28, 10:25 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:15 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:45 PM | 5 days ago |
News
2 hours ago seekingalpha.com
Geron: Opportunity Builds Even As Struggles Continue
Geron achieved FDA approval for RYTELO (imetelstat) in June 2024, targeting lower-risk myelodysplastic syndromes (LR-MDS). RYTELO is Geron's only advanced-stage asset, marking a pivotal milestone.…
5 hours ago defenseworld.net
Geron (GERN) Expected to Announce Earnings on Wednesday
Geron (NASDAQ: GERN - Get Free Report) is expected to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Geron to post earnings of ($0.01) per share and…
-
4 days ago benzinga.com
Wedbush Maintains Outperform on Geron, Lowers Price Target to $5
Wedbush analyst Robert Driscoll maintains Geron (NASDAQ:GERN) with a Outperform and lowers the price target from $6 to $5.
4 days ago benzinga.com
Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth
Geron Corporation (NASDAQ:GERN) shares plunged on Wednesday after the company halted its late-stage cancer program.
4 days ago benzinga.com
Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth
Geron stock plunges as the company halts its Phase 3 IMpactMF trial, refocusing its resources on commercial hematology and global expansion.
4 days ago benzinga.com
Crude Oil Surges Over 3%; Brinker Posts Upbeat Earnings
U.S. stocks were mixed; Dow and S&P 500 rose while Nasdaq slipped. Brinker beat estimates and raised guidance; oil jumped 3.4%.
5 days ago reuters.com
Geron discontinues late-stage trial of blood cancer drug
Geron said on Wednesday it would discontinue a late-stage trial testing its treatment for patients with a form of rare blood cancer.
5 days ago globenewswire.com
Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis
FOSTER CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage hematology biopharmaceutical company, today announced the decision to discontinue the Phase…
1 week ago globenewswire.com
Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026
FOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood…
1 week ago globenewswire.com
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood…
2 weeks ago prnewswire.com
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be…
2 weeks ago businesswire.com
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has…
3 weeks ago globenewswire.com
Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia
Presentations feature real-world experience and clinical evidence in lower-risk MDS, underscoring growing global scientific engagement with imetelstat FOSTER CITY, Calif. , Oct. 12, 2026 (GLOBE…
3 weeks ago benzinga.com
Geron Q2 2026 Earnings Call: Complete Transcript
Geron (NASDAQ:GERN) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time…
1 month ago gurufocus.com
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireNEW YORK, Sept. 25, 2026Shareholders are encouraged to contact the firm
1 month ago gurufocus.com
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
Geron Investigation Initiated: Kahn Swick and Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERNPR NewswireNEW YORK and NEW ORLEANS, Se
1 month ago prnewswire.com
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be…
1 month ago prnewswire.com
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
NEW YORK and NEW ORLEANS, Sept. 25, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.
1 month ago globenewswire.com
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood…
1 month ago marketbeat.com
Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands
Geron NASDAQ: GERN executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company…
1 month ago gurufocus.com
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ), announces that K
1 month ago businesswire.com
Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has…
1 month ago marketbeat.com
Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands
Geron NASDAQ: GERN said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company…
2 months ago gurufocus.com
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, Sept. 2, 2026
-
5 months ago benzinga.com
Geron To Present Real-World Moffitt Cancer Center Study Showing RYTELO (imetelstat) Safety And Efficacy In Lower-Risk MDS At EHA 2026
Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population Additional…
6 months ago benzinga.com
Geron Reports Q1 2026 Results: Full Earnings Call Transcript
Geron Reports Q1 2026 Results: Full Earnings Call Transcript
-
6 months ago benzinga.com
Geron Q1 EPS $(0.01) Beats $(0.02) Estimate, Sales $51.771M Beat $50.582M Estimate
Geron (NASDAQ:GERN) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 66.67 percent increase over losses of $(0.03) per…
6 months ago benzinga.com
Fastenal, Replimune Group, Children's Place And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures lower, with Dow futures down 150 points. Fastenal shares dip 4% after meeting earnings estimate. Other stocks also down.
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
8 months ago benzinga.com
Geron Q4 EPS $(0.05) Misses $(0.03) Estimate, Sales $48.015M Miss $50.420M Estimate
Geron (NASDAQ:GERN) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.03) by 47.06 percent. This is a 25 percent decrease over losses of $(0.04) per…
-
8 months ago benzinga.com
Earnings Scheduled For February 25, 2026
Earnings Scheduled For February 25, 2026
8 months ago benzinga.com
Top 2 Tech Stocks That May Fall Off A Cliff This Quarter
Top 2 Tech Stocks That May Fall Off A Cliff This Quarter
8 months ago benzinga.com
Top 2 Industrials Stocks That Are Ticking Portfolio Bombs
Top 2 Industrials Stocks That Are Ticking Portfolio Bombs
8 months ago benzinga.com
Top 3 Health Care Stocks That May Collapse This Quarter
Top 3 Health Care Stocks That May Collapse This Quarter
10 months ago benzinga.com
Investor Says He 'Doubled' His Savings After Using ChatGPT in Stock Research – Shares Top 5 Stock Picks
Investor Says He 'Doubled' His Savings After Using ChatGPT in Stock Research – Shares Top 5 Stock Picks
-
10 months ago benzinga.com
Geron Implements Strategic Restructuring, Cutting Workforce By One-Third And Incurring ~$18M In Charges
On December 16, 2025, Geron Corporation (the "Company") began implementation of a strategic restructuring plan intended to position the Company for long-term value creation for patients and…
10 months ago benzinga.com
Why Planet Labs Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Why Planet Labs Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
-
10 months ago benzinga.com
Geron Showcases New ASH 2025 Data Highlighting RYTELO's Durable Efficacy And Survival Trends Across LR-MDS And Myelofibrosis
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including…
12 months ago benzinga.com
Earnings Scheduled For November 5, 2025
Earnings Scheduled For November 5, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
1 year ago benzinga.com
Dow Dips Over 100 Points; TJX Earnings Top Views
Dow Dips Over 100 Points; TJX Earnings Top Views
1 year ago benzinga.com
Nasdaq Surges 150 Points; Lowe's Posts Upbeat Earnings
Nasdaq Surges 150 Points; Lowe's Posts Upbeat Earnings
-
1 year ago benzinga.com
Earnings Scheduled For February 26, 2025
Earnings Scheduled For February 26, 2025
-
2 years ago benzinga.com
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
-
2 years ago benzinga.com
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session